Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Cancer Discov. 2020 May 8;10(9):1374–1387. doi: 10.1158/2159-8290.CD-19-1352

Figure 2. CHD1 promotes an immunosuppressive TME in prostate cancer.

Figure 2.

(A) Top 15 down-regulated pathways in PtenChd1pc−/− prostate tumors. Pathways highlighted in red are immune response related pathways. NES: normalized enrichment score. (B-D) Immunoprofiling of Ptenpc−/− vs. PtenChd1pc−/− prostate tumors using CyTOF. (B,C) viSNE plots colored by relative expression of CyTOF markers, with populations indicated, and (D) quantification of each tumor infiltrating immune cell population. (E,F) Immunoprofiling of PtenSmad4pc−/− vs. PtenSmad4Chd1pc−/− prostate tumors using CyTOF. (E) viSNE plots and (F) quantification of tumor infiltrating immune cell populations. PS, PtenSmad4pc−/−; PSC, PtenSmad4Chd1pc−/−